Robotic Knee Replacement Surgery in India and UAE | Complete Patient Guide

• ELIGIBLE CANDIDATES:

• Patients with end-stage osteoarthritis of the knee confirmed by weight-bearing X-rays (Kellgren–Lawrence Grade III or IV)

• Patients with post-traumatic arthritis, avascular necrosis (AVN) of the femoral condyle, or inflammatory arthropathy (rheumatoid/psoriatic arthritis) unresponsive to DMARDs and biologics

• Patients with a persistent Oxford Knee Score (OKS) ≤ 26 or WOMAC pain/function subscale indicating severe disability despite 3–6 months of supervised conservative therapy

• Age typically 50–80 years, though robotic UKA may be offered to younger, active patients with isolated medial compartment disease to preserve bone stock

• BMI ≤ 40 kg/m² (obesity increases perioperative risk; bariatric optimization is recommended for BMI > 40 before proceeding)

• Medically optimized patients: HbA1c < 8.0% for diabetics, hemoglobin ≥ 10 g/dL, blood pressure controlled, active infections eradicated

• REQUIRED PRE-OPERATIVE DIAGNOSTICS:

• Weight-bearing anteroposterior (AP), lateral, and Rosenberg view knee X-rays (mandatory for Kellgren–Lawrence grading and deformity assessment)

• Long-leg (hip-to-ankle) standing radiograph for mechanical axis measurement and deformity planning

• CT scan of the knee (thin-slice, typically 0.625 mm) for 3D preoperative planning with the robotic system software (e.g., Mako application, ROSA planning suite)

• MRI knee: considered in cases of ligament integrity assessment, osteonecrosis staging, or when UKA candidacy is uncertain

• Full blood count (FBC), renal function (eGFR), liver function tests (LFTs), coagulation profile (PT/INR/aPTT), HbA1c, blood group and cross-match

• Electrocardiogram (ECG) and echocardiography (ECHO) for patients >60 years or with known cardiac history (assessment of ejection fraction, valvular disease)

• Chest X-ray, urinalysis and urine culture (to exclude urinary tract infection before implant surgery)

• Anesthesia fitness assessment: Goldman Cardiac Risk Index, STOP-BANG score for obstructive sleep apnea

• Dental clearance recommended to rule out occult dental sepsis as a source of hematogenous implant infection

• CONTRAINDICATIONS:

• Active systemic or local infection (absolute contraindication; periprosthetic joint infection risk is catastrophic)

• Insufficient bone stock or severe metaphyseal bone loss requiring reconstruction (may necessitate revision-class implants rather than primary robotic TKA)

• Severe peripheral vascular disease compromising wound healing

• Unresolved bleeding disorders or inability to discontinue anticoagulation perioperatively

• Severe neurological conditions affecting the operated limb (e.g., foot drop, advanced peripheral neuropathy) that would prevent rehabilitation

• Morbid obesity (BMI > 45–50 kg/m²) without prior optimization

• Patients with unrealistic functional expectations or inadequate social support for rehabilitation

ROBOTIC SYSTEM PLATFORMS IN USE:

The three dominant robotic platforms used globally and available in top India and UAE centers are:

1. Stryker Mako SmartRobotics (haptic arm system): CT-based preoperative 3D planning with intraoperative acetabular and tibial boundary enforcement via haptic resistance; the most published platform with the largest evidence base. Validated for TKA, UKA, and total hip arthroplasty.

2. Smith+Nephew CORI (imageless, handheld robotic system): Requires no preoperative CT; uses intraoperative bone morphing and kinematic data capture to create a real-time 3D plan. Reduces radiation exposure and cost of planning CT.

3. Zimmer Biomet ROSA Knee (image-based or imageless): Optical tracking with robotic arm guidance; supports both TKA and UKA with open implant compatibility.

SURGICAL APPROACHES:

• Total Knee Arthroplasty (TKA) — Robotic-Assisted: Indicated for tricompartmental or bicompartmental disease. Resection of distal femur and proximal tibia with robotic-guided cuts to achieve planned mechanical axis correction. Soft tissue balancing is performed in extension and flexion gaps before final implant cementation. Implant options include cruciate-retaining (CR), posterior-stabilized (PS), and medial-pivot designs (e.g., Medacta GMK Sphere) for improved kinematic fidelity.

• Unicompartmental Knee Arthroplasty (UKA) — Robotic-Assisted: Resurfacing of the medial or lateral compartment only, preserving both cruciate ligaments and the unaffected compartments. The Mako UKA has demonstrated 98.8% implant survivorship at 10 years in registry data, significantly outperforming conventional UKA. Faster recovery, less blood loss, and better proprioception retention vs. TKA.

• Patellofemoral Arthroplasty (PFA): Isolated resurfacing of the patellofemoral joint for isolated trochlear OA; less commonly performed but available in specialized centers.

• Computer-Navigated TKA (non-robotic but advanced): Uses optical or electromagnetic navigation without a robotic arm. Less precise than robotic systems but superior to conventional jig-based surgery; offered in centers without robotic capability as an intermediate option.

IMPLANT SELECTION & FIXATION:

• Cemented fixation: Gold standard for primary TKA, with >95% survivorship at 15 years.

• Cementless/press-fit fixation: Increasingly used in younger, active patients (<65 years) with good bone quality; trabecular metal (Zimmer Biomet Trabecular Metal, Stryker Tritanium) surfaces promote osseointegration.

• Highly cross-linked polyethylene (HXLPE) inserts: Reduce wear particle generation and osteolysis, contributing to improved long-term implant survival.

• Oxidized zirconium (Oxinium, Smith+Nephew): Metal ion-free bearing surface for patients with nickel/cobalt allergy.

ANESTHESIA & BLOOD MANAGEMENT:

• Spinal anesthesia with sedation is preferred over general anesthesia; associated with lower DVT rates, less blood loss, shorter recovery room time.

• Periarticular injection (PAI) cocktails: Ropivacaine + ketorolac + epinephrine + morphine injected into capsule and soft tissues intraoperatively for 48-hour local analgesia, reducing opioid consumption.

• Tranexamic acid (TXA): IV and/or topical administration is standard practice to reduce perioperative blood loss by 30–50%, dramatically decreasing transfusion rates.

• Tourniquet use: Increasingly surgeon-dependent; tourniquet-free TKA is practiced in many robotic centers to reduce ischemia-reperfusion injury and quadriceps weakness.

PRE-ARRIVAL (2–4 WEEKS BEFORE SURGERY):

• GAF Healthcare coordinator reviews your MRI, X-rays, blood reports, and medical history remotely and obtains a virtual consultation with your assigned robotic orthopedic surgeon

• Surgical plan confirmed; CT scan for robotic planning may be done locally in your home country and uploaded digitally, or arranged upon arrival

• Medical visa application submitted (India: e-Medical Visa within 72 hours typically); UAE entry visa or visa-on-arrival arranged

• Preadmission investigations (blood work, ECG, ECHO if required) scheduled for Day 1–2 after arrival

• Medications review: antiplatelet agents (aspirin, clopidogrel) held 5–7 days preoperatively; warfarin bridging protocol activated if indicated; NSAIDs stopped 5 days prior

ARRIVAL & PREOPERATIVE PHASE (Days 1–2):

• Airport pickup by GAF Healthcare driver; check-in to partner hospital or adjacent hotel (attendant accommodation arranged)

• Day 1: Anesthesia assessment, blood transfusion screening, pre-admission nursing assessment, physiotherapy baseline assessment (ROM, muscle strength grading)

• Day 2: Admission to hospital; consent process with surgeon and anesthetist; robotic CT scan planning review finalized; nil-by-mouth from midnight

• Pre-op optimization: carbohydrate loading drinks up to 2 hours before surgery (Enhanced Recovery After Surgery — ERAS protocol); compression stockings and low-molecular-weight heparin (LMWH) prophylaxis initiated

INTRAOPERATIVE (Surgery Day — typically Day 3):

• Duration: 90–150 minutes (robotic setup adds approximately 10–15 minutes but improves precision significantly)

• Spinal anesthesia administered; tourniquet applied (surgeon preference)

• Robotic system registered using bony landmarks; real-time 3D bone model confirmed against CT plan

• Femoral and tibial bone cuts executed within haptic boundary (Mako) or robotic guidance envelope; cuts accurate to < 0.5 mm and < 1° of plan

• Trial components inserted; soft tissue balancing assessed in multiple flexion angles; gaps quantified digitally

• Final implants cemented (or press-fit); wound closed in layers; drain may or may not be placed per surgeon preference

• Periarticular injection administered before closure; tranexamic acid given IV

IMMEDIATE POSTOPERATIVE (Day 3 — Day of Surgery):

• Recovery room: vital sign monitoring, pain assessment (NRS), neurovascular checks of the operated limb

• Foley catheter removed same day or Day 1 post-op

• Ice therapy/cryotherapy applied; limb elevation

• DVT prophylaxis: LMWH (enoxaparin) or rivaroxaban initiated within 6–12 hours of surgery

• Clear fluids and light diet commenced same evening

EARLY MOBILIZATION (Days 3–5 — Hospital Stay):

• Day 1 post-op (Day 4 of journey): Physiotherapist assists patient to standing and takes first steps with walking frame; this early weight-bearing is a critical ERAS milestone that reduces hospital length of stay and improves outcomes

• Stair climbing practice initiated before discharge

• Active ROM exercises: target 0–90° flexion before discharge

• Wound assessed daily; drain removed (if used) within 24–48 hours

• Pain managed with multimodal analgesia: paracetamol, selective COX-2 inhibitors (celecoxib), gabapentin, opioids only as rescue

• Discharge criteria: ROM >90°, ability to mobilize safely with walking aid, pain controlled on oral analgesia, no signs of wound complication or DVT

POST-DISCHARGE IN COUNTRY (Weeks 1–6):

• Week 1–2: Daily outpatient physiotherapy at hospital or GAF partner clinic; wound review and staple/suture removal at Day 10–14; continue LMWH or oral anticoagulant (rivaroxaban/apixaban typically for 2–5 weeks depending on DVT risk stratification)

• Week 2: Target ROM 0–100°; walking with one crutch or walking stick; swelling reduction assessed; Doppler ultrasound for DVT screening if clinically indicated

• Week 3–4: ROM target 0–110°; stationary cycling initiated; ascending and descending stairs independently; short-haul fit-to-fly assessment available from Week 3 with physician clearance and compression stocking prescription for flight

• Week 5–6: ROM target 0–120°; long-haul fit-to-fly clearance; formal discharge letter and rehabilitation plan provided for home country physiotherapist; digital follow-up arranged with GAF Healthcare at 6 weeks, 3 months, and 1 year

LONG-TERM RECOVERY MILESTONES:

• 6 weeks: Driving (left knee — earlier; right knee — typically 6 weeks)

• 3 months: Return to low-impact activities (swimming, cycling, walking)

• 6 months: Full functional recovery in most patients; PROM reassessment (OKS, KSS)

• 12 months: Final outcome assessment; implant X-ray review